2020
DOI: 10.1038/s41598-020-69199-1
|View full text |Cite
|
Sign up to set email alerts
|

Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants

Abstract: functional tests for lupus anticoagulants (LA) as part of a thrombophilia workup are commonly performed in patients under anticoagulant therapy that may interfere with assay results. there is no consensus on how these tests should be assessed in patients on direct oral anticoagulants (DoAcs). in this retrospective cohort study, we analysed data from patients with a history of thrombosis in whom dilute Russell viper venom time (dRVVt), LA-sensitive aptt, and solid phase assays for antiphospholipid antibodies (a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 28 publications
0
8
0
Order By: Relevance
“…Hence, accurate aPL testing is mandatory to avoid inappropriate use of these anticoagulant compounds in this population (4,5). While detection of solid-phase antibodies aCL and aβ 2 -GPI is not affected by FXa inhibitor compounds present in tested samples (13,14), it is well-established that rivaroxaban and apixaban have the potential to compromise LA testing leading to unreliable results (false-positive/negative results) even at very low concentrations (15)(16)(17)(18)(19)(20)(21)(22). Due to their heterogeneity, LA testing should be performed using, at least, two coagulation assays of differing analytical principles, the first based on dilute Russell Viper Venom Time (dRVVT) and the second derived from activated partial thromboplastin time (aPTT) (6,18,23).…”
Section: Introductionmentioning
confidence: 99%
“…Hence, accurate aPL testing is mandatory to avoid inappropriate use of these anticoagulant compounds in this population (4,5). While detection of solid-phase antibodies aCL and aβ 2 -GPI is not affected by FXa inhibitor compounds present in tested samples (13,14), it is well-established that rivaroxaban and apixaban have the potential to compromise LA testing leading to unreliable results (false-positive/negative results) even at very low concentrations (15)(16)(17)(18)(19)(20)(21)(22). Due to their heterogeneity, LA testing should be performed using, at least, two coagulation assays of differing analytical principles, the first based on dilute Russell Viper Venom Time (dRVVT) and the second derived from activated partial thromboplastin time (aPTT) (6,18,23).…”
Section: Introductionmentioning
confidence: 99%
“…[127][128][129] To reduce likelihood of interference, samples for LA testing should be taken at a distance from LMWH administration (at least 12 hours). 126 A TT can help identify suspected undisclosed UFH, but it is less affected by LMWHs and may be normal. Local studies of anticoagulant effects on reagents in local use may be useful in guiding interpretation strategies.…”
Section: Heparinsmentioning
confidence: 99%
“…Generally, dRVVT and dPT are more sensitive to DFXaIs than aPTTs. 126,130 Rivaroxaban commonly elevates dRVVT screen more than confirm, leading to false-positive interpretations, although some reagents exhibit similarly elevated screen and confirm results in normal plasma with DFXaIs and interpretation is unaffected. 126,128,[130][131][132][133] The false positivity has been observed even at trough rivaroxaban levels.…”
Section: Direct Oral Anticoagulantsmentioning
confidence: 99%
See 1 more Smart Citation
“…The only finding of note was his lupus anticoagulant was weakly positive via dilute APTT only. This test result was likely due to the patient being on a factor Xa inhibitor which can cause false positives 9 10…”
Section: Investigationsmentioning
confidence: 99%